20% Rise in Insulin Use by 2030, Study Says

Henrietta Brewer
November 23, 2018

People with type 2 diabetes may be treated with insulin if they have uncontrolled blood glucose levels, and have not been able to lower their glucose levels using metformin or other medication.

Using data from the International Diabetes Federation and 14 studies to get a picture of type 2 diabetes numbers across 221 countries, the team modeled the burden of type 2 diabetes from 2018 to 2030.

The number of people with type 2 diabetes who receive insulin is expected to increase by more than 20% by 2030, a report suggests.

The figures were presented in a study published on Wednesday in the journal Lancet Diabetes and Endocrinology.

Globally China, India and the USA with the highest population are more prone to diabetes 2 due to the obesity and the sedentary work lifestyle.

Insulin is very much essential for patients to combat type 2 diabetes and it will help the diabetic victims to reduce complications associated with this disease like kidney failure, blindness and stroke. Researchers noted that the usage of methyldopa is capable of preventing up to 60 percent of type 1 diabetes among people who are at the risk of the disease.

A global diabetes epidemic is fueling record demand for insulin, but tens of millions will not get the injections they need unless there is a dramatic improvement in access and affordability, a new study concludes.

Type 2 diabetes comprises the majority of people with diabetes around the world, and is caused largely due to excess body weight and physical inactivity.

"These assessments propose that current dimensions of insulin access are exceptionally insufficient contrasted with anticipated need, especially in Asia and Africa, and more endeavors ought to be dedicated to defeating this approaching health challenge", states Dr. Sanjay Basu from Stanford University, USA main lead of the study.

The untreated person affected by diabetes were affected by the deterioration of heart, kidney, eyes, nerves, blood vessels, stroke, and the major complication is that these high sugar level patients can not undergo surgery because the healing of a surgical wound is slow and complicated.

Sanjay Basu also added that governments should begin effective initiatives to make insulin affordable for patients all across the world.

Only three companies now produce insulin: Novo Nordisk, Sanofi and Lilly.

Other reports by iNewsToday